Page last updated: 2024-11-12
seletracetam
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
Seletracetam: Antiepileptic Agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 9942725 |
| CHEMBL ID | 3918017 |
| CHEBI ID | 188602 |
| SCHEMBL ID | 387920 |
| MeSH ID | M0508882 |
Synonyms (26)
| Synonym |
|---|
| seletracetam |
| ucb-44212 |
| 357336-74-4 |
| D05817 |
| seletracetam (usan/inn) |
| CHEBI:188602 |
| (2s)-2-[(4s)-4-(2,2-diluoroethenyl)-2-oxopyrrolidin-1-yl]butanamide |
| rfr2ch3qzk , |
| ucb 44212 |
| seletracetam [usan:inn] |
| 1-pyrrolidineacetamide, 4-(2,2-difluoroethenyl)-alpha-ethyl-2-oxo-, (alphas,4s)- |
| unii-rfr2ch3qzk |
| (2s)-2-((4s)-4-(2,2-difluoroethenyl)-2-oxopyrrolidin-1-yl)butanamide |
| seletracetam [inn] |
| seletracetam [usan] |
| DB05885 |
| SCHEMBL387920 |
| CHEMBL3918017 |
| DTXSID30905079 |
| (s)-2-((s)-4-(2,2-difluorovinyl)-2-oxopyrrolidin-1-yl)butanamide |
| HY-119810 |
| CS-0078059 |
| MS-23326 |
| (2s)-2-[(4s)-4-(2,2-difluoroethenyl)-2-oxopyrrolidin-1-yl]butanamide |
| anwpenapcifdsz-rqjhmyqmsa-n |
| AKOS040742623 |
Research Excerpts
Overview
Seletracetam is a pyrrolidone derivative with a one-log-unit higher affinity for the synaptic vesicle protein 2A (SV2A) than levetiracetam.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Seletracetam is a pyrrolidone derivative with a one-log-unit higher affinity for the synaptic vesicle protein 2A (SV2A) than levetiracetam (Keppra). " | ( Profile of the new pyrrolidone derivative seletracetam (ucb 44212) in animal models of epilepsy. Kenda, B; Klitgaard, H; Löscher, W; Margineanu, DG; Matagne, A; Michel, P; Potschka, H, 2009) | 2.06 |
Bioavailability
| Excerpt | Reference | Relevance |
|---|---|---|
| " Initial studies in humans demonstrated first-order monocompartmental kinetics with a half-life of 8 h and an oral bioavailability of >90%." | ( Seletracetam (UCB 44212). Bennett, B; Cornet, M; Leonard, M; Matagne, A; Meeus, MA; Michel, P; Toublanc, N, 2007) | 1.78 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Drug Classes (2)
| Class | Description |
|---|---|
| organonitrogen compound | Any heteroorganic entity containing at least one carbon-nitrogen bond. |
| organooxygen compound | An organochalcogen compound containing at least one carbon-oxygen bond. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Research
Studies (9)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (55.56) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 1 (11.11) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 115.67
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (115.67) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 2 (22.22%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (77.78%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||